FDA strengthens the role of analytical comparability in biosimilar development
Analytical Comparability at the Center of Modern Biosimilar Development The U.S. Food and Drug Administration (FDA) has recently updated its guidance with a set of new and revised draft Q&As on Biosimilar Development [1]. A key focus of this update is the clarification of conditions under which a non‑U.S. authorized reference product may be used […]